Dr. Rizvi Discusses Pembrolizumab for Non-Small Cell Lung Cancer

Naiyer A. Rizvi, MD
Published: Friday, Aug 29, 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Rizvi says pembrolizumab is being explored in NSCLC in first-line and previously treated patients. The patients who express PD-L1 do very well on the agent, Rizvi says.

Pembrolizumab is also well tolerated in both first-line and pretreated NSCLC patients. The toxicity profile is favorable, Rizvi says, with low significant AE rates.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Rizvi says pembrolizumab is being explored in NSCLC in first-line and previously treated patients. The patients who express PD-L1 do very well on the agent, Rizvi says.

Pembrolizumab is also well tolerated in both first-line and pretreated NSCLC patients. The toxicity profile is favorable, Rizvi says, with low significant AE rates.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x